Synagis is a shot that helps prevent serious lung infections caused by respiratory syncytial virus (RSV). RSV is very contagious. It is spread by contact with infected fluids from the nose or mouth and through droplets in the air from coughing.
RSV infections generally occur in the US from November to April.
Usually, RSV causes mild symptoms, such as a runny nose and fever. But babies born early and babies with lung or heart problems have a higher risk of getting very sick if they get infected with RSV.
Synagis is given to children less than 1 year old at high risk for serious complications from RSV. These children include:
Some premature babies born 11 or more weeks before their due date
Premature babies born 8 or more weeks before their due date, have lung disease, and needed oxygen after they were born
Babies who have a heart problems and who will need heart surgery
Children with other heart, lung, immune, or muscle problems that increase the chance of lung infections
In some cases, Synagis may be given to children up to 2 years old if they have immune system problems or continue to require medical treatment for lung problems.
This medicine is not a treatment for children who already have a serious RSV infection.
The shot may be given with other routine immunizations. A child may need a shot every month during RSV season to be fully protected.
How does it work?
Synagis is a virus-fighting antibody. Full-term babies get antibodies from their mothers during pregnancy. These antibodies help babies fight RSV and other infections. Babies born prematurely often do not get enough of these antibodies before birth. It’s harder for these babies and other young children at high risk to fight infections and keep infections from getting serious. Synagis helps these children fight RSV infection.
What else do I need to know about this medicine?
Ask your healthcare provider about Synagis. This medicine is very expensive. Insurance companies will pay for treatment only if a baby meets specific criteria. Your healthcare provider will have the most recent recommendations.
Written by Robert Brayden, MD, Professor of Pediatrics, University of Colorado.
Pediatric Advisor 2015.1 published by RelayHealth. Last modified: 2014-08-05 Last reviewed: 2014-08-05
This content is reviewed periodically and is subject to change as new health information becomes available. The information is intended to inform and educate and is not a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional.
Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., … & HernÃ¡ndez-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638.